Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Tag: AACR Annual Meeting 2026
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR...
At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay...
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents...
At the AACR Annual Meeting 2026, we conducted "Bite-sized Research" interviews with attendees for morsels of knowledge about their...
Researchers are building AI agents to assess how patients could respond to therapy and aid doctors in making cancer...
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to...
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...